Isoniazid orally dissolving strip - Oak Therapeutics

Drug Profile

Isoniazid orally dissolving strip - Oak Therapeutics

Alternative Names: INH ODS

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oak Therapeutics
  • Class Antibacterials; Antituberculars; Carboxylic acids; Hydrazines; Isonicotinic acids; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 23 Aug 2017 Oak Therapeutics plans to apply for SBIR phase II grant for isoniazid oral dissolvable strip development
  • 01 Oct 2016 Oak Therapeutics receives phase I SBIR grant from National Institute for Allergens and Infectious Diseases for isoniazid oral dissolvable strip development in Tuberculosis
  • 01 May 2016 Preclinical trials in Tuberculosis (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top